Robert Beardsley, MD
Ophthalmology · Eugene, ORNPI 1437302825
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (53.7%), speaking fees and education — rather than concentrated in one kind of arrangement. AbbVie accounts for 61.1% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2019 at $2,236 and has fallen 83.3% since, to $374 in 2025.
Across 87 payments — averaging $44.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novartis$360
- Regeneron Healthcare Solutions, Inc.$300
- Alimera Sciences, Inc.$223
- Genentech USA, Inc.$149
- Eyepoint US, Inc.$146
- plus $314 from 7 others
What the payments were for
- Speaking & faculty fees$1,75046%
- Food & beverage$2,06354%
- Education$261%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 27 | $2,347 |
| Novartis | 12 | $360 |
| Regeneron Healthcare Solutions, Inc. | 9 | $300 |
| Alimera Sciences, Inc. | 10 | $223 |
| Genentech USA, Inc. | 11 | $149 |
| Eyepoint US, Inc. | 9 | $146 |
| Rxsight Inc | 1 | $100 |
| Genentech, Inc. | 1 | $67 |
| ANI Pharmaceuticals, Inc. | 2 | $45 |
| Apellis Pharmaceuticals, Inc. | 2 | $43 |
| Mallinckrodt Hospital Products Inc. | 1 | $22 |
| Coherus Oncology, Inc. | 1 | $22 |
| Vyera Pharmaceuticals, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,839 in reported general payments places this provider in the 85th percentile of 248 ophthalmology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Difluprednate | 148 | $15,948 |
| Prednisolone Acetate | 220 | $7,754 |
| ProlensaBromfenac Sodium | 11 | $3,789 |
| Ketorolac Tromethamine | 74 | $1,947 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 140 | $1,798 |
| Fluorometholone | 20 | $1,663 |
| ValacyclovirValacyclovir Hcl | 24 | $1,630 |
| Loteprednol Etabonate | 13 | $1,597 |
| Travoprost | 12 | $1,475 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 73 | $1,150 |
| Latanoprost | 85 | $1,059 |
| Dorzolamide Hcl | 50 | $865 |
| Ofloxacin | 54 | $825 |
| Brimonidine Tartrate | 48 | $666 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 78 | $664 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Eugene
- Balamurali AmbatiEugene$19K
- Richard HoffmanEugene$17K
- Eric NiespodzonyEugene$10K
- Justin EtzelEugene$6K
- Jason GrossEugene$6K
- John HainesEugene$6K
- Joseph MandoEugene$4K
- Shelley JelineoEugene$4K
- Kent KarrenEugene$4K
- Brian WalkerEugene$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.